PetCure Oncology says it has treated more than 10,000 patients
CURRENT FULL VERSION: PetCure Oncology has crossed a symbolic threshold: more than 10,000 patients treated with radiation therapy. In a January 7, 2026, announcement, the company said the milestone reflects a decade-long effort to make advanced veterinary radiation oncology more available outside academia, particularly through stereotactic radiosurgery, or SRS, and stereotactic radiation therapy, or SRT. The network is part of Thrive Pet Healthcare and has positioned itself as a national referral option for practices that don't have local radiation capability. (petcureoncology.com)
That framing matters because access really was limited when the company launched. PetCure’s 2015 launch materials said fewer than 10 specialty centers in the U.S. were offering SRS for pets, while its current veterinarian FAQ says there were fewer than 70 traditional veterinary radiation therapy facilities nationwide when the company was founded. Independent literature also supports the idea that stereotactic radiation was still an emerging modality in veterinary medicine in the late 2010s, with a 2018 survey describing SRT as a novel, high-precision technique used in relatively few centers. (petcureoncology.com)
PetCure’s core pitch has been that stereotactic protocols can compress treatment into one to three fractions for many cases, versus the much longer schedules associated with conventional fractionated radiation. The company says that shorter course can reduce anesthetic events and overall treatment time for dogs and cats, which is a meaningful operational and quality-of-life consideration for pet parents and referring teams alike. Earlier company materials described the network reaching 8,000 treated pets in 2024, suggesting roughly 2,000 additional cases were added between that milestone and the new 10,000-patient announcement. In separate company commentary, chief medical officer Neal Mauldin has tied that adoption directly to the realities of veterinary access: fewer specialists, less sophisticated equipment outside major population centers, and the need for protocols that still work for families who may live 8 to 10 hours from a radiation facility. He has described that travel burden as a major driver behind stereotactic approaches that can often be delivered in two to four days rather than over three to four weeks. (petcureoncology.com)
The broader market context suggests both growth and constraints. The Veterinary Cancer Society’s current radiation facilities list shows a wider spread of treatment centers than existed a decade ago, but access remains patchy, particularly outside major metro areas. Commentary from the field has highlighted the geographic imbalance directly, noting that pet parents in rural regions may still face long travel distances for SRS. At the same time, workforce capacity remains a bottleneck; even market analyses, while not primary scientific sources, point to the small number of board-certified veterinary radiation oncologists as a limit on how quickly advanced radiation services can scale. (vetcancersociety.org)
PetCure and Thrive also appear to be investing in a next-generation technology story, not just a scale story. In late 2025, Thrive and Empyrean Medical Systems announced plans to bring the Sirius advanced radiation platform to PetCure’s Seattle site in early 2026, describing it as a human-grade precision system with robotic delivery, Monte Carlo-based treatment planning, and real-time image guidance. PetCure has also highlighted another access-oriented technology trend for 2025: compact, self-contained mobile radiation units designed for superficial tumors, surgical scars, and many head-and-neck cancers. According to the company, those systems may not require a dedicated radiation vault and could potentially allow CT, treatment planning, and treatment delivery during a single anesthetic event. Together, those signals suggest the company wants to reinforce its position not only as a national network, but as a technology-forward one. (empyreanmed.com)
On expert perspective, most of the public commentary available comes from within the PetCure-Thrive ecosystem rather than outside analysts. Chief medical officer Neal Mauldin has repeatedly argued that shorter stereotactic protocols have been a major driver of adoption because they can be delivered in days rather than weeks. In PetCure’s 2025 trends piece, the company also pointed to related developments that it believes could broaden radiation oncology’s role: combining radiation with immunotherapy to expose tumor antigens and then target them with a vaccine approach, with a planned study in cats with oral squamous cell carcinoma; low-dose radiation therapy for chronic inflammatory, non-cancerous conditions such as feline cystitis, stomatitis, and osteoarthritis in dogs and cats; and growing interest in low dose-rate radiation therapy during induction treatment for canine B-cell lymphoma, which the company said has shown improved survival in two peer-reviewed papers. Those comments should be read with the understanding that they come from a company executive, but they align with the practical realities many referral clinicians see in case selection, client decision-making, and the search for shorter or more versatile treatment pathways. (petcureoncology.com)
Why it matters: For veterinary professionals, this milestone is a marker of how referral oncology has changed. A decade ago, radiation therapy, especially stereotactic treatment, was often a niche option tied to teaching hospitals or a handful of specialty centers. Today, more community and corporate referral networks can at least offer a pathway to advanced radiation consultation. That can expand options for patients with tumors in locations where surgery is difficult, for cases where shorter treatment courses may improve client acceptance, and for practices trying to keep continuity with the primary veterinarian after specialty intervention. It may also widen the clinical conversation around where radiation fits beyond classic external beam oncology, including investigational combinations with immunotherapy and selected non-malignant inflammatory conditions. At the same time, access is still shaped by cost, geography, specialist staffing, and the need for stronger published outcomes data across tumor types and protocols. (petcureoncology.com)
What to watch: The next questions are whether PetCure adds more centers, how quickly new platforms like Sirius are deployed after the planned Seattle debut, and whether the company or independent groups publish more peer-reviewed outcomes that help veterinarians compare stereotactic protocols with surgery, chemotherapy, immunotherapy, or conventionally fractionated radiation in specific case types. Also worth watching is whether some of the company’s 2025 trend lines move from concept to routine use, particularly mobile radiation systems, radiation-immunotherapy combinations, and low dose-rate approaches in lymphoma. (empyreanmed.com)